Peptide library / Digestive & weight / Lixisenatide
Lixisenatide
A short-acting GLP-1 receptor agonist taken once daily, no longer sold in the United States.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Lower blood sugar after meals in type 2 diabetesFDA approved
How it is thought to work
Lixisenatide activates the GLP-1 receptor and mainly lowers the rise in blood sugar after meals by slowing stomach emptying.
What the evidence shows
The ELIXA trial in people with a recent acute coronary event found no increase or decrease in major cardiovascular events compared with placebo.
Safety and unknowns
Nausea and vomiting are common. Hypoglycemia risk rises when combined with insulin or sulfonylureas.
Regulatory status
FDA-approved in 2016 as Adlyxin. The manufacturer discontinued it in the United States in 2023, though a combination with insulin glargine remains available.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Lutetium Lu-177 dotatate
FDA-approvedA radioactive peptide that delivers radiation directly to neuroendocrine tumors.
Maridebart cafraglutide
In clinical trialsAn investigational monthly injection that pairs a GLP-1 agonist with an antibody that blocks the GIP receptor.
Liraglutide
FDA-approvedA daily GLP-1 receptor agonist, the first of the class approved for chronic weight management.
General information, not medical advice. Do not buy or inject unregulated peptides.